Eli Lilly Mounjaro Dawa Lene Se Pehle Soch Lo! India Mein Sasti Generic Ne Machaya Shor, Price Dhadaam!

HEALTHCAREBIOTECH
Whalesbook Logo
AuthorVihaan Mehta|Published at:
Eli Lilly Mounjaro Dawa Lene Se Pehle Soch Lo! India Mein Sasti Generic Ne Machaya Shor, Price Dhadaam!
Overview

Eli Lilly ki blockbuster dawa Mounjaro, jo obesity ke liye use hoti hai, woh India mein thodi pressure mein aa gayi hai. Jab se patent expiry hui hai, tab se market mein Ozempic aur Wegovy jaise semaglutide ke saste generic versions aa gaye hain, jin ki prices **50-80%** tak kam hain. Is wajah se Mounjaro ki sales mein dikhne wala dip aaya hai aur generic versions dhoom macha rahe hain.

Instant Stock Alerts on WhatsApp

Used by 10,000+ active investors

1

Add Stocks

Select the stocks you want to track in real time.

2

Get Alerts on WhatsApp

Receive instant updates directly to WhatsApp.

  • ✓Quarterly Results
  • ✓Concall Announcements
  • ✓New Orders & Big Deals
  • ✓Capex Announcements
  • ✓Bulk Deals
  • ✦And much more
Add StocksGet it on Google PlayDownload on the App Store

Patent Expiry Ka Kamaal: Generic Dawaon Ka Flood!

Dekho bhai, India mein semaglutide ka patent March 20 ko khatam ho gaya. Bas kya tha, India ke local pharma companies ne Ozempic aur Wegovy ke generic versions launch kar diye. Aur bhai, prices ko itna neeche le gaye hain ki original brands se 50% se lekar 80% tak kam ho gayi hain.

Sales Ka Game Badla!

Industry tracker Pharmarack Technologies ne bataya ki March mein Tirzepatide (Mounjaro) ki sales mein kaafi girawat aayi hai. February mein jo ₹135 crore thi, woh March mein gir kar sirf ₹114 crore reh gayi. Ye lagbhag 16% ka dip hai. Wahi, semaglutide ki sales March mein ₹59 crore ho gayi, jo February mein ₹48 crore thi. Overall GLP-1 agonist ki segment ki sales bhi March mein ₹180 crore thi, jo February ke ₹191 crore se kam hai.

Kaun Hai King Market Mein?

Abhi tak lagbhag 13 companies ne 26 tarah ke generic semaglutide versions launch kar diye hain, aur aur bhi aane wale hain. March mein Novo Nordisk ne Ozempic, Wegovy, aur Rybelsus se sabse zyada ₹45 crore ki sales ki. Lekin bhai, Indian companies bhi peeche nahi hain. Torrent Pharma ne ₹4.7 crore, Dr. Reddy's Laboratories ne ₹1.9 crore, Zydus Lifesciences ne ₹1.4 crore, Lupin ne ₹1.4 crore, aur Sun Pharma ne ₹0.90 crore ki sales ki hai.

Sheetal Sapale, jo Pharmarack mein Commercial ke Vice-President hain, unhone isko "classic 'gold rush phase'" bola hai. Unka kehna hai ki bahut log enter kar rahe hain, par asli fayda kuch hi badi companies ko hoga.

Aage Kya?

Authorities ne kaha hai ki ye dawaan sirf eligible patients ko hi di jaani chahiye, par galat istemaal ki chinta abhi bhi hai. Experts bol rahe hain ki rules banenge, par usse generic launches ki speed rukne wali nahi hai. Lagta hai April 2026 tak ye growth exponential ho jayegi. Innovator companies jaise Novo Nordisk ab partners ke saath milkar apni quality aur market share badhane par focus kar rahi hain. Prices aage chal kar ek bada factor banengi.

Get stock alerts instantly on WhatsApp

Quarterly results, bulk deals, concall updates and major announcements delivered in real time.

Add Stocks
Disclaimer:This content is for educational and informational purposes only and does not constitute investment, financial, or trading advice, nor a recommendation to buy or sell any securities. Readers should consult a SEBI-registered advisor before making investment decisions, as markets involve risk and past performance does not guarantee future results. The publisher and authors accept no liability for any losses. Some content may be AI-generated and may contain errors; accuracy and completeness are not guaranteed. Views expressed do not reflect the publication’s editorial stance.